IL154113A0 - Tie-2 ligands, methods for their preparation and uses thereof - Google Patents

Tie-2 ligands, methods for their preparation and uses thereof

Info

Publication number
IL154113A0
IL154113A0 IL15411303A IL15411303A IL154113A0 IL 154113 A0 IL154113 A0 IL 154113A0 IL 15411303 A IL15411303 A IL 15411303A IL 15411303 A IL15411303 A IL 15411303A IL 154113 A0 IL154113 A0 IL 154113A0
Authority
IL
Israel
Prior art keywords
tie
provides
human
growth
ligand
Prior art date
Application number
IL15411303A
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/319,932 external-priority patent/US5643755A/en
Priority claimed from US08/348,492 external-priority patent/US5879672A/en
Priority claimed from US08/373,579 external-priority patent/US5650490A/en
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Priority to IL15411303A priority Critical patent/IL154113A0/xx
Publication of IL154113A0 publication Critical patent/IL154113A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL15411303A 1994-10-07 2003-01-23 Tie-2 ligands, methods for their preparation and uses thereof IL154113A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL15411303A IL154113A0 (en) 1994-10-07 2003-01-23 Tie-2 ligands, methods for their preparation and uses thereof

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US08/319,932 US5643755A (en) 1994-10-07 1994-10-07 Nucleic acid encoding tie-2 ligand
US08/330,261 US5521073A (en) 1994-10-07 1994-10-27 TIE-2 ligand, and method of making
US08/348,492 US5879672A (en) 1994-10-07 1994-12-02 Tie-2 ligand 1
US35350394A 1994-12-09 1994-12-09
US08/373,579 US5650490A (en) 1994-10-07 1995-01-17 Tie-2 ligand 2
US08/418,595 US5814464A (en) 1994-10-07 1995-04-06 Nucleic acids encoding TIE-2 ligand-2
IL11551795A IL115517A (en) 1994-10-07 1995-10-05 Tie-2 ligands, methods for their preparation and uses thereof
IL15411303A IL154113A0 (en) 1994-10-07 2003-01-23 Tie-2 ligands, methods for their preparation and uses thereof

Publications (1)

Publication Number Publication Date
IL154113A0 true IL154113A0 (en) 2003-07-31

Family

ID=27559710

Family Applications (4)

Application Number Title Priority Date Filing Date
IL11551795A IL115517A (en) 1994-01-17 1995-10-05 Tie-2 ligands, methods for their preparation and uses thereof
IL14013700A IL140137A (en) 1994-10-07 2000-12-06 Receptor bodies specifically binding tie-2 ligands
IL14013800A IL140138A (en) 1994-10-07 2000-12-06 Specific antibodies of tie-2 ligands
IL15411303A IL154113A0 (en) 1994-10-07 2003-01-23 Tie-2 ligands, methods for their preparation and uses thereof

Family Applications Before (3)

Application Number Title Priority Date Filing Date
IL11551795A IL115517A (en) 1994-01-17 1995-10-05 Tie-2 ligands, methods for their preparation and uses thereof
IL14013700A IL140137A (en) 1994-10-07 2000-12-06 Receptor bodies specifically binding tie-2 ligands
IL14013800A IL140138A (en) 1994-10-07 2000-12-06 Specific antibodies of tie-2 ligands

Country Status (23)

Country Link
US (4) US5814464A (xx)
EP (1) EP0784683B1 (xx)
JP (1) JP4054375B2 (xx)
CN (1) CN1230536C (xx)
AT (1) ATE199259T1 (xx)
AU (1) AU711111B2 (xx)
CA (1) CA2202028C (xx)
CZ (1) CZ292453B6 (xx)
DE (1) DE69520149T2 (xx)
DK (1) DK0784683T3 (xx)
ES (1) ES2154354T3 (xx)
FI (1) FI120313B (xx)
GR (1) GR3035717T3 (xx)
HK (1) HK1005944A1 (xx)
HU (1) HU221422B1 (xx)
IL (4) IL115517A (xx)
MX (1) MX9702530A (xx)
NO (1) NO322643B1 (xx)
NZ (1) NZ296638A (xx)
PL (1) PL184642B1 (xx)
PT (1) PT784683E (xx)
WO (1) WO1996011269A2 (xx)
ZA (1) ZA958444B (xx)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681714A (en) * 1992-07-30 1997-10-28 Mount Sinai Hospital Corporation Nucleic acid encoding tek receptor tyrosine kinase
US6221839B1 (en) 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
US6130071A (en) * 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US6245530B1 (en) 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
DE69633121T2 (de) * 1995-04-06 2005-07-28 Regeneron Pharmaceuticals, Inc. Tie-2 liganden, herstellungsverfahren und verwendung
AU755337B2 (en) * 1995-04-06 2002-12-12 Regeneron Pharmaceuticals, Inc. New uses of tie-2 ligands
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
DE69634412T3 (de) 1995-09-29 2013-07-04 Vegenics Pty Ltd Regulierte gene und ihre verwendungen
US7063965B2 (en) * 1996-04-05 2006-06-20 Regeneron Pharmaceuticals, Inc. Nucleic acid encoding TIE-2 ligand
DE19623850A1 (de) * 1996-06-14 1997-12-18 Wacker Chemie Gmbh Homogenisierung von Dispersionen
US5851797A (en) * 1996-06-19 1998-12-22 Regeneron Pharmaceuticals, Inc. Tie ligand-3, methods of making and uses thereof
ES2194203T3 (es) 1996-06-19 2003-11-16 Regeneron Pharma Ligando del receptor tie-2 (ligando-4 de tie) y su uso.
US6846914B2 (en) 1996-06-19 2005-01-25 Regeneron Pharmaceuticals, Inc. Tie-2 ligand-3
US6265564B1 (en) * 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule
DK0956339T3 (da) 1996-08-23 2006-01-30 Licentia Oy Rekombinant vaskulær endotelcellevækstfaktor D (VEGF-D)
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US6350450B1 (en) 1997-09-19 2002-02-26 Genentech, Inc. TIE ligand homologue antibody
US5972338A (en) 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US6057435A (en) * 1997-09-19 2000-05-02 Genentech, Inc. Tie ligand homologues
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
US6348350B1 (en) 1997-09-19 2002-02-19 Genentech, Inc. Ligand homologues
AU2000399A (en) * 1997-12-19 1999-07-12 Regeneron Pharmaceuticals, Inc. Receptor tyrosine kinase, ar-1, is a regulator of angiogenesis
WO1999032515A2 (en) * 1997-12-19 1999-07-01 Zymogenetics, Inc. Angiopoietin homolog, dna encoding it, and method of making it
WO1999040193A1 (en) * 1998-02-04 1999-08-12 Zymogenetics, Inc. Angiopoietin homolog zapo3, dna encoding it, and method of making it
JP2002516067A (ja) * 1998-03-02 2002-06-04 ミレニアム・フアーマシユーチカルズ・インコーポレーテツド 新規ｆｄｒｇタンパク質および核酸分子、ならびにそのための用途
WO1999045132A1 (en) 1998-03-02 1999-09-10 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
ATE451389T1 (de) 1998-11-10 2009-12-15 Ludwig Inst Cancer Res Von blutplättchen abstammender wachstumsfaktor d, dafür kodierende dns und deren verwendungen
AU776393B2 (en) 1998-12-23 2004-09-09 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of ligands
IL144849A0 (en) * 1999-03-02 2002-06-30 Regeneron Pharma Angiopoietin-related protein and nucleic acids
US6455035B1 (en) 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
CA2372053C (en) 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
NZ516258A (en) 1999-06-07 2004-02-27 Immunex Corp Tek antagonists
EP1956030B1 (en) 1999-06-15 2009-11-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
US6689035B1 (en) 2000-04-11 2004-02-10 Gerber Scientific Products, Inc. Method and apparatus for designing and creating a package
US7026462B2 (en) 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
AU2006228095B2 (en) * 2001-10-11 2010-11-04 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7052695B2 (en) 2001-10-25 2006-05-30 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of treating hypertension
JP4242590B2 (ja) 2002-01-11 2009-03-25 俊一 塩澤 慢性関節リウマチの疾患感受性遺伝子、及びその利用
US7427594B1 (en) * 2002-02-26 2008-09-23 The Trustees Of The University Of Pennsylvania Methods and pharmaceuticals compositions for treating coronary artery disease, ischemia,and vascular disease using angiopoietins
US7081443B2 (en) 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
US20040115640A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of angiopoietin-2 expression
EP1545588A4 (en) 2002-07-23 2007-12-05 Ludwig Inst Cancer Res METHODS AND COMPOSITIONS FOR ACTIVATION OR INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR D AND VASCULAR ENDOTHELIAL GROWTH FACTOR C
WO2004045531A2 (en) 2002-11-14 2004-06-03 Cornell Research Foundation, Inc. Protection of cardiac myocardium
MEP31408A (en) 2003-07-18 2010-10-10 Abgenix Inc Specific binding agents to hepatocyte growth factor
CN1323723C (zh) * 2003-12-26 2007-07-04 上海新世界基因技术开发有限公司 Tie2受体介导的靶向性肿瘤基因治疗的基因转移系统
US8298532B2 (en) * 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
WO2005087177A2 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
BRPI0513534A (pt) 2004-07-20 2008-05-06 Genentech Inc inibidores de proteìna 4 semelhante à angiopoietina, combinações, e seu uso
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
RS52036B (en) * 2004-12-21 2012-04-30 Medimmune Limited ANGIOPOETIN-2 ANTIBODIES AND ITS USES
MX2007008326A (es) * 2005-01-07 2008-01-16 Univ Emory Antagonistas de cxcr4 para el tratamiento de una infeccion por vih.
JP4657757B2 (ja) * 2005-02-23 2011-03-23 株式会社膠原病研究所 肺高血圧症発症関連遺伝子を用いた肺高血圧症の診断および治療
JP2006325528A (ja) * 2005-05-27 2006-12-07 Institute For Rheumatic Diseases Co Ltd 糖尿病性網膜症の診断および予防
JP4657857B2 (ja) * 2005-08-25 2011-03-23 株式会社膠原病研究所 メタボリックシンドロームの診断および予防
CN101370519B (zh) 2005-12-15 2013-07-24 阿斯利康(瑞典)有限公司 治疗癌症的促血管生成素-2拮抗剂和VEGF-A、KDR和/或Flt1拮抗剂的组合
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
CA2651629A1 (en) 2006-05-09 2007-11-22 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
TWI595005B (zh) 2007-08-21 2017-08-11 安健股份有限公司 人類ｃ－ｆｍｓ抗原結合蛋白質
US8227577B2 (en) * 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
ES2689274T3 (es) 2008-01-03 2018-11-13 The Scripps Research Institute Dirección de anticuerpos mediante un dominio de reconocimiento modular
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
CA2712000A1 (en) 2008-01-28 2009-08-06 Medimmune Limited Stabilized angiopoietin-2 antibodies and uses thereof
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CA2729012A1 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
RU2598248C2 (ru) * 2009-04-02 2016-09-20 Роше Гликарт Аг Полиспецифичные антитела, включающие антитела полной длины и одноцепочечные фрагменты fab
PL2417156T3 (pl) 2009-04-07 2015-07-31 Roche Glycart Ag Trójwartościowe, bispecyficzne przeciwciała
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8980268B2 (en) 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
US20120189635A1 (en) 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
CA2781519A1 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
WO2011038139A1 (en) 2009-09-23 2011-03-31 Amgen Inc. Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
AR080794A1 (es) * 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
MX340558B (es) 2010-08-24 2016-07-14 F Hoffmann-La Roche Ag * Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
CN103403025B (zh) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 单价抗原结合蛋白
KR101638224B1 (ko) 2011-02-28 2016-07-08 에프. 호프만-라 로슈 아게 항원 결합 단백질
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
EP2726088B1 (en) 2011-06-29 2019-01-02 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
WO2013112438A1 (en) 2012-01-23 2013-08-01 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ang2 antibodies
KR20140127854A (ko) 2012-02-10 2014-11-04 제넨테크, 인크. 단일-쇄 항체 및 다른 이종다량체
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
AU2013230750B2 (en) 2012-03-08 2018-02-01 Medimmune, Llc Methods of treatment with Angiopoietin-2 antibodies
HUE044263T2 (hu) 2012-03-30 2019-10-28 Boehringer Ingelheim Int ANG2-kötõ molekulák
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
PE20150361A1 (es) 2012-07-13 2015-03-14 Roche Glycart Ag Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares
WO2014108854A1 (en) 2013-01-09 2014-07-17 Fusimab Ltd. Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
EP3424530A1 (en) 2013-03-15 2019-01-09 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
JP6422956B2 (ja) 2013-10-11 2018-11-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性ドメイン交換共通可変軽鎖抗体
ES2792227T3 (es) 2014-09-26 2020-11-10 Somalogic Inc Predicción de evento de riesgo cardiovascular y usos de la misma
CA2964470A1 (en) 2014-10-17 2016-04-21 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
US20190004048A1 (en) 2015-06-26 2019-01-03 Amgen Inc. Biomarker of Survival in the Treatment of Renal Cell Carcinoma with a VEGFR Inhibitor and an Ang2 Inhibitor
CN108366968B (zh) 2015-12-16 2022-02-18 瑞泽恩制药公司 制造蛋白质微粒的组合物和方法
AU2017315075B2 (en) 2016-08-23 2020-10-01 Medimmune Limited Anti-VEGF-A and anti-ANG2 antibodies and uses thereof
IL299270B2 (en) 2017-01-30 2024-10-01 Regeneron Pharmaceuticals Inc Preparations and methods for reducing biological load in chromatography
AU2018347521A1 (en) 2017-10-12 2020-05-07 Immunowake Inc. VEGFR-antibody light chain fusion protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
WO1995013387A1 (en) * 1993-11-12 1995-05-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tie-2, a novel receptor tyrosine kinase
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
AU750414B2 (en) * 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids

Also Published As

Publication number Publication date
FI971406A (fi) 1997-06-04
IL140137A0 (en) 2002-02-10
HUT77491A (hu) 1998-05-28
MX9702530A (es) 1998-02-28
NZ296638A (en) 1999-03-29
CZ102597A3 (en) 1997-09-17
DE69520149D1 (de) 2001-03-29
IL140138A0 (en) 2002-02-10
US5814464A (en) 1998-09-29
DE69520149T2 (de) 2001-08-30
DK0784683T3 (da) 2001-03-19
IL115517A0 (en) 1996-01-19
IL115517A (en) 2004-12-15
JP4054375B2 (ja) 2008-02-27
CA2202028C (en) 2011-12-20
ATE199259T1 (de) 2001-03-15
CA2202028A1 (en) 1996-04-18
PT784683E (pt) 2001-07-31
FI971406A0 (fi) 1997-04-04
CN1230536C (zh) 2005-12-07
PL184642B1 (pl) 2002-11-29
ZA958444B (en) 2014-06-25
JPH10509583A (ja) 1998-09-22
AU4129596A (en) 1996-05-02
ES2154354T3 (es) 2001-04-01
WO1996011269A2 (en) 1996-04-18
HK1005944A1 (en) 1999-02-05
IL140138A (en) 2005-03-20
US6166185A (en) 2000-12-26
HU221422B1 (en) 2002-09-28
NO322643B1 (no) 2006-11-13
AU711111B2 (en) 1999-10-07
NO971557D0 (no) 1997-04-04
NO971557L (no) 1997-06-06
US6433143B1 (en) 2002-08-13
EP0784683A1 (en) 1997-07-23
IL140137A (en) 2005-03-20
US6645484B1 (en) 2003-11-11
CZ292453B6 (cs) 2003-09-17
PL319586A1 (en) 1997-08-18
GR3035717T3 (en) 2001-07-31
FI120313B (fi) 2009-09-15
EP0784683B1 (en) 2001-02-21
CN1167505A (zh) 1997-12-10

Similar Documents

Publication Publication Date Title
IL154113A0 (en) Tie-2 ligands, methods for their preparation and uses thereof
HK1008230A1 (en) Tie-2 ligands, methods of making and uses thereof.
IL127623A0 (en) Tie-2 receptor ligands (tie ligand-3; tie ligand-4) and their uses
WO1997017446A3 (en) HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF
LU91117I2 (en) Cetuximab in combination with irinotecan.
DE3268915D1 (en) Angiotropins of leukocytes and inflamed tissue: a new class of natural chemotropic protein mitogens for specific induction of directional growth of blood vessels, neovascularization of tissues and morphogenesis of blood vessel patterns, process for their biotechnical preparation and pharmaceutical compositions
GR3024204T3 (en) Lymphocyte-associated cell surface protein
MXPA02008239A (es) Gen humano de la esquizofrenia.
AU2001233912A1 (en) Diagnosis of breast cancer using bcmp-81 as marker
WO2002100343A3 (en) N-terminally truncated galectin-3 and antibodies for treating cancer
WO2002026193A3 (en) Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
WO1999050289A3 (en) Transformation progression-related genes and their use